Nutritional Risks in Youth
Study Finds Nutritional Deficiencies Among Children Prescribed GLP-1 Weight Loss Drugs
Anonymous
Key Points
1
The study drew on national administrative claims data covering more than 100 million patients from 2017 through 2022; the final cohort included children who had continuous insurance enrollment and no prior diagnosis of nutritional deficiency.
2
Among the identified deficiencies and complications, nutritional anemia accounted for 1.55% of cases and iron-deficiency anemia for 1.44%, according to the study’s detailed results.
3
Liraglutide was the most commonly prescribed GLP-1 medication in the cohort, accounting for 78.6% of prescriptions, followed by dulaglutide at 10.4% and semaglutide at 9.1%.
4
The researchers said the findings are particularly relevant as pediatric use of GLP-1 drugs expands during periods of rapid growth and puberty, and called for nutritional support to begin when treatment starts rather than after a deficiency is diagnosed.
5
The broader pediatric context is substantial: the article cites Centers for Disease Control and Prevention data showing obesity among about 22% of U.S. adolescents ages 12 to 19 and 21% of children ages 6 to 11.
One in six children who take GLP-1 drugs like Ozempic for weight loss or diabetes developed a nutritional deficiency within a year, according to a new study. Medical Daily reported that vitamin D deficiency was the most common problem, affecting 12.4% of young patients. The findings raise concerns as these medications gain popularity among children during crucial growth years.
Researchers from Lurie Children's Hospital analyzed insurance claims for 2,031 children ages 10 to 17 who started GLP-1 treatment. They found that only 5% of patients received nutritional counseling within 30 days of starting the drug, and fewer than 25% got counseling within six months. Experts say monitoring should begin immediately when treatment starts, not after deficiencies appear.
Vitamin D Deficiency Dominates Among Young GLP-1 Users
Vitamin D deficiency emerged as the leading nutritional problem in the study, occurring in nearly 1 out of 8 children on GLP-1 drugs. Find Articles noted that iron-related problems and anemia were less common but still significant. Nutritional anemia affected 1.55% of patients, while iron-deficiency anemia struck 1.44%. These gaps matter greatly during adolescence, when bones are developing rapidly and calcium, iron, and vitamin D are essential for proper growth.
Liraglutide Led Prescriptions Across the Young Patient Group
The study examined three main GLP-1 drugs prescribed to children. WTVR reported that liraglutide accounted for 78.6% of all prescriptions in the group. Dulaglutide made up 10.4% of prescriptions, while semaglutide represented 9.1%. The heavy reliance on liraglutide suggests doctors should pay special attention to nutritional monitoring in this largest group of young patients.
GLP-1 Use Expanding Rapidly Among Heavier Children
The context for this study is the growing childhood obesity crisis. Fox 13 Now cited CDC data showing that about 22% of U.S. adolescents ages 12 to 19 are obese, as are 21% of children ages 6 to 11. These numbers explain why doctors increasingly prescribe GLP-1 drugs to young patients. The medication helps them lose weight, but the nutritional costs deserve close attention and management.
Study Shows Association, Not Direct Proof of Causation
The research examined insurance claims data from 2017 through 2022, covering more than 100 million patients. Researchers focused on children with no prior nutritional deficiency diagnosis. Because the study was observational—tracking what actually happened rather than running a controlled experiment—it cannot definitively prove that GLP-1 drugs caused the deficiencies. It shows an association, leaving room for other factors to play a role. Still, experts urge immediate nutritional support once young patients start treatment.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
16
Articles
11
Reach
27
A
AnonymousAuthor
